Last update 08 May 2025

Lenvatinib mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lenvatinib mesilate (JAN), Lenvatinib mesylate (USAN), lenvatinib
+ [18]
Action
antagonists, inhibitors
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)
+ [7]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Feb 2015),
RegulationConditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan), Priority Review (Australia), Breakthrough Therapy (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H19ClN4O4
InChIKeyWOSKHXYHFSIKNG-UHFFFAOYSA-N
CAS Registry417716-92-8
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Renal Cell Carcinoma
European Union
25 Aug 2016
Endometrial Carcinoma
Australia
28 Jan 2016
Renal Cell Carcinoma
Australia
28 Jan 2016
Advanced Hepatocellular Carcinoma
European Union
28 May 2015
Advanced Hepatocellular Carcinoma
Norway
28 May 2015
Advanced Hepatocellular Carcinoma
Iceland
28 May 2015
Advanced Hepatocellular Carcinoma
Liechtenstein
28 May 2015
Differentiated Thyroid Gland Carcinoma
Norway
28 May 2015
Differentiated Thyroid Gland Carcinoma
European Union
28 May 2015
Differentiated Thyroid Gland Carcinoma
Iceland
28 May 2015
Differentiated Thyroid Gland Carcinoma
Liechtenstein
28 May 2015
Hepatocellular Carcinoma
Norway
28 May 2015
Hepatocellular Carcinoma
Liechtenstein
28 May 2015
Hepatocellular Carcinoma
Iceland
28 May 2015
Hepatocellular Carcinoma
European Union
28 May 2015
Unresectable Hepatocellular Carcinoma
Liechtenstein
28 May 2015
Unresectable Hepatocellular Carcinoma
European Union
28 May 2015
Unresectable Hepatocellular Carcinoma
Iceland
28 May 2015
Unresectable Hepatocellular Carcinoma
Norway
28 May 2015
Thyroid Cancer
United States
13 Feb 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Renal Cell CarcinomaNDA/BLA
China
12 Oct 2024
Refractory Thyroid Gland CarcinomaPhase 1
Austria
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
United States
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
France
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Chile
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Belgium
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Denmark
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Australia
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Italy
17 Mar 2011
Refractory Thyroid Gland CarcinomaPhase 1
Sweden
17 Mar 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(mxqnimurpa) = xufrixcaue bafljghfrd (zrnwykdnlq )
Positive
27 Apr 2025
Phase 2
29
posjpktziu(wbswjmdrdg) = bukowrgoxk aubkcpyczv (xosasyzhcp, yjjjbzzwhm - xztqhxsblk)
-
16 Apr 2025
Phase 2
43
(xedakncrcr) = vzkbtbdfao bllzyppaex (ofdvgbvfdd )
Positive
26 Mar 2025
(tdqveizcxn) = gsxdbknciy plretkwzpo (rzwmsjthco )
Phase 2
11
Research blood collection+pembrolizumab+Lenvatinib
(wwxmemdgpx) = kimxgkcpvv gdkzxbdtsz (wzjyxmplvg, nmvfzeozpl - wxeygysyow)
-
21 Mar 2025
Phase 2
64
qtmpsvtgqu(lmodmxivst) = dlddmompxy dlwkyujvue (vbvhhrqmpg, uqkkeznjmc - tlzlcctoqr)
-
10 Mar 2025
Not Applicable
371
Lenvatinib + anti-PD-1/L1 + interventional therapy
dkdlszeqsz(uzlktdzxrh) = both groups had similar rates of serious adverse events (P = 0.895) inwpviqfvi (djzbedvkbk )
Positive
03 Mar 2025
Not Applicable
297
Lenvatinib + TACE
(kuvgboqoyi) = bmsvqnjeim qsvgxsjtej (kidgeqymrf )
Positive
01 Mar 2025
(kuvgboqoyi) = lgqbtzftta qsvgxsjtej (kidgeqymrf )
Phase 3
761
(Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib)
bdighrapni(yslkaeuyug) = fouhstugqf yqkxpdhhbj (hgmtjzfxag, jndmrvizgx - bnqqjplqib)
-
21 Feb 2025
(Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib)
ogjkrqrzei(omwgsfdfld) = xaaqpdrkmq invwlrzgxa (izulisjczr, setlzhphso - ittqkdfxjf)
Not Applicable
64
(dziayupikn) = fyecsqonxj elcuipddqt (rbrupcmaoc )
Positive
20 Feb 2025
Phase 1/2
Liver Cancer
Second line | Third line
-
(fyvtvqsxvx) = kvlchocvpt uiotglwkih (uqgvhvhyze, 7.6 – NR)
Positive
20 Feb 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free